The size of the worldwide biosurgery market is anticipated to rise significantly in the near future due to significant investments made in the medical device industry by both public and private entities, a rise in researcher spending on R&D, and aggressive tactics used by leading companies, such as the introduction of new products. The rise in the demand for elective surgeries, the prevalence of chronic diseases, the funding from government and private organizations for the construction of healthcare infrastructure, and the growing geriatric population are the main factors driving the growth of the global biosurgery market share.
Because there is a greater need for biosurgery products due to the rise in traumatic injury cases, the prevalence of severe traumatic injuries is driving the expansion of the biosurgery market share.
Because there is a greater need for biosurgery products due to the rise in traumatic injury cases, the prevalence of severe traumatic injuries is driving the expansion of the biosurgery market share. The existence of significant manufacturing firms producing cutting-edge biosurgery products also supports the expansion of the biosurgery industry. Additionally, the growing number of elderly people, who are more vulnerable to long-term illnesses, is driving the expansion of the biosurgery industry.
Additionally, during the projected period, the growth of the medical device and pharmaceutical industries as well as the advancement of research and development efforts in these fields are anticipated to offer profitable prospects for the worldwide biosurgery market to expand. Additionally, the number of sports-related injuries and surgical procedures is rising, which is driving the expansion of the biosurgery sector.
The biosurgery industry is expanding as a result of initiatives implemented by both public and commercial entities to advance the medical device sector. Nevertheless, during the biosurgery market forecast, high product costs and rigorous regulations are anticipated to limit market expansion. Because there is a greater need for biosurgery products due to the rise in traumatic injury cases, the prevalence of severe traumatic injuries is driving the expansion of the biosurgery market share.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Biosurgery Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Biosurgery Market details, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
Biosurgery Market based on Application:
- Neuro And Spine Surgery
- Orthopedic Surgery
- General Surgery
- Cardiovascular And Thoracic Surgery
- Analog Imaging
Biosurgery Market based on Source:
- Biologics Products
- Synthetic Products
Biosurgery Market based on Product Type:
- Bone Graft Substitutes
- Hemostatic And Surgical Sealant
- Mesh
- Anti Adhesive Agents
Biosurgery Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Due to a spike in demand for bone graft substitute goods and an increase in sports injuries and operations, the bone graft substitutes sector was the largest contributor to the market in 2020, depending on the kind of product. This trend is anticipated to continue during the forecast period.
However, due to the rising prevalence of procedures like general abdominal and cardiovascular surgeries, which raise the demand for anti-adhesive agents in the biosurgery market, the anti-adhesive agents sector is anticipated to rise significantly over the forecast period.
According to application, the market was led by the neuro and spine surgery segment in 2020, and because to the rising frequency of neurological disorders, this trend is anticipated to persist during the forecast period.
However, because of the rising incidence of surgeries, the rise in sedentary lifestyles, and the aging population, the general surgery segment is anticipated to have significant development throughout the projected period.
Due to the growing demand for natural goods and the advancement of technology in the pharmaceutical industry, the biologics products category held a dominant market share in 2020 and is anticipated to maintain this trend over the course of the forecast period.
On the other hand, due to advancements in R&D activities for manufacturing a variety of surgical items, the synthetic products category is anticipated to experience significant increase throughout the forecast period.
Due to factors such as the rise in the number of surgeries performed, the prevalence of chronic diseases, the presence of major manufacturers of biosurgery products, and the expansion of R&D efforts in the healthcare industry, North America led the biosurgery market in 2020 and is predicted to continue doing so throughout the forecast period. But between 2021 and 2030, Asia-Pacific is predicted to grow at the fastest rate of 10.2% due to a growing senior population, an increase in sports-related surgeries and injuries, and a growth in demand for biosurgery products.
This research features prominent firms such as B. Braun Melsungen AG, Baxter International Inc., Hemostasis LLC, Integra LifeSciences Holdings Corp., Johnson & Johnson, Medtronic PLC, Sanofi S.A., Tissue Regenix Group, and Aroa Biosurgery Limited.
- This report illustrates the most vital attributes of the Biosurgery Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Biosurgery Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Biosurgery Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Biosurgery Market.
List of Tables
TABLE 1. BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 2. BIOSURGERY MARKET VALUE FOR NEURO AND SPINE SURGERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. BIOSURGERY MARKET VALUE FOR ORTHOPEDIC SURGERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. BIOSURGERY MARKET VALUE FOR GENERAL SURGERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. BIOSURGERY MARKET VALUE FOR CARDIOVASCULAR AND THORACIC SURGERY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. BIOSURGERY MARKET VALUE FOR ANALOG IMAGING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 8. BIOSURGERY MARKET VALUE FOR BIOLOGICS PRODUCTS, 2021-2030 (USD BILLION)
TABLE 9. BIOSURGERY MARKET VALUE FOR SYNTHETIC PRODUCTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 11. BIOSURGERY MARKET VALUE FOR BONE GRAFT SUBSTITUTES, 2021-2030 (USD BILLION)
TABLE 12. BIOSURGERY MARKET VALUE FOR HEMOSTATIC AND SURGICAL SEALANT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. BIOSURGERY MARKET VALUE FOR MESH, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. BIOSURGERY MARKET VALUE FOR ANTI ADHESIVE AGENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. NORTH AMERICA BIOSURGERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 16. NORTH AMERICA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 19. U.S BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 20. U.S BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 21. U.S BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 22. CANADA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 23. CANADA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. CANADA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 25. MEXICO BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 26. MEXICO BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 27. MEXICO BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 28. EUROPE BIOSURGERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 29. EUROPE BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 30. EUROPE BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. EUROPE BIOSURGERY MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 32. GERMANY BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 33. GERMANY BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. GERMANY BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 35. U.K BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 36. U.K BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. U.K BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 38. FRANCE BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 39. FRANCE BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 40. FRANCE BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 41. ITALY BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 42. ITALY BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. ITALY BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 44. SPAIN BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 45. SPAIN BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 46. SPAIN BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 47. ROE BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 48. ROE BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 49. ROE BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 50. ASIA PACIFIC BIOSURGERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 51. ASIA PACIFIC BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 54. CHINA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 55. CHINA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. CHINA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 57. INDIA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 58. INDIA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. INDIA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 60. JAPAN BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 61. JAPAN BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 62. JAPAN BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 63. REST OF APAC BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 64. REST OF APAC BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 66. LATIN AMERICA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 67. LATIN AMERICA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 69. BRAZIL BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 70. BRAZIL BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 72. ARGENTINA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 73. ARGENTINA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 75. MIDDLE EAST AND AFRICA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 76. MIDDLE EAST AND AFRICA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 78. SAUDI ARABIA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 79. SAUDI ARABIA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 81. UAE BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 82. UAE BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 83. UAE BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 84. REST OF MIDDLE EAST AND AFRICA BIOSURGERY MARKET VALUE, BY SOURCE, 2021-2030 (USD BILLION)
TABLE 85. REST OF MIDDLE EAST AND AFRICA BIOSURGERY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA BIOSURGERY MARKET VALUE, BY PRODUCT TYPE, 2021-2030 (USD BILLION)
TABLE 87. JOHNSON & JOHNSON: FINANCIALS
TABLE 88. JOHNSON & JOHNSON: PRODUCTS & SERVICES
TABLE 89. JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 90. BAXTER INTERNATIONAL INC.: FINANCIALS
TABLE 91. BAXTER INTERNATIONAL INC.: PRODUCTS & SERVICES
TABLE 92. BAXTER INTERNATIONAL INC.: RECENT DEVELOPMENTS
TABLE 93. MEDTRONIC PLC: FINANCIALS
TABLE 94. MEDTRONIC PLC: PRODUCTS & SERVICES
TABLE 95. MEDTRONIC PLC: RECENT DEVELOPMENTS
TABLE 96. BECTON, DICKINSON & CO.: FINANCIALS
TABLE 97. BECTON, DICKINSON & CO.: PRODUCTS & SERVICES
TABLE 98. BECTON, DICKINSON & CO.: RECENT DEVELOPMENTS
TABLE 99. B. BRAUN MELSUNGEN AG: FINANCIALS
TABLE 100. B. BRAUN MELSUNGEN AG: PRODUCTS & SERVICES
TABLE 101. B. BRAUN MELSUNGEN AG: RECENT DEVELOPMENTS
TABLE 102. STRYKER CORP.: FINANCIALS
TABLE 103. STRYKER CORP.: PRODUCTS & SERVICES
TABLE 104. STRYKER CORP.: RECENT DEVELOPMENTS
TABLE 105. INTEGRA LIFESCIENCES HOLDINGS CORP.: FINANCIALS
TABLE 106. INTEGRA LIFESCIENCES HOLDINGS CORP.: PRODUCTS & SERVICES
TABLE 107. INTEGRA LIFESCIENCES HOLDINGS CORP.: DEVELOPMENTS
TABLE 108. CSL LTD.: FINANCIALS
TABLE 109. CSL LTD.: PRODUCTS & SERVICES
TABLE 110. CSL LTD.: RECENT DEVELOPMENTS
TABLE 111. HEMOSTASIS L.L.C.: FINANCIALS
TABLE 112. HEMOSTASIS L.L.C.: PRODUCTS & SERVICES
TABLE 113. HEMOSTASIS L.L.C.: RECENT DEVELOPMENTS
TABLE 114. PFIZER INC.: FINANCIALS
TABLE 115. PFIZER INC.: PRODUCTS & SERVICES
TABLE 116. PFIZER INC.: RECENT DEVELOPMENTS
